Abstract
BackgroundIt is now established that patients with hyperlipidemia have a high risk of atherosclerosis and thrombotic complications, which are two important events responsible for the onset and progression of cardiovascular disease. In the context of managing dyslipidemia by means of dietary advice based on the consumption of argan oil, we wanted to investigate the effect of virgin argan oil on plasma lipids, and for the first time, on the platelet hyperactivation and oxidative status associated with dyslipidemia. This study concerns patients recruited in the area of Rabat in Morocco.Methods39 dyslipidemic (79% women) patients were recruited for our study in the area of Rabat in Morocco. They were randomly assigned to the two following groups: the argan group, in which the subjects consumed 25 mL/day of argan oil at breakfast for 3 weeks, and the control group in which argan oil was replaced by butter.ResultsAfter a 3-week consumption period, blood total cholesterol was significantly lower in the argan oil group, as was LDL cholesterol (23.8% and 25.6% lower, respectively). However, the HDL cholesterol level had increased by 26% at the end of the intervention period compared to baseline. Interestingly, in the argan oil group thrombin-induced platelet aggregation was lower, and oxidative status was enhanced as a result of lower platelet MDA and higher GPx activity, respectively.ConclusionsIn conclusion, our results, even if it is not representative of the Moroccan population, show that argan oil can prevent the prothrombotic complications associated with dyslipidemia, which are a major risk factor for cardiovascular disease.
Highlights
It is established that patients with hyperlipidemia have a high risk of atherosclerosis and thrombotic complications, which are two important events responsible for the onset and progression of cardiovascular disease
In-vivo platelet activation has been reported in type-IIa hypercholesterolemic patients [11], suggesting that high levels of oxidized Low-density lipoprotein (LDL), via changes in the composition of platelet membrane phospholipids and cholesterol, may increase the platelet reactivity associated with enhanced thromboxane A2 (TxA2) biosynthesis
According to the International Diabetes Federation (IDF) definition [40], all of the patients exhibited at least two components of metabolic syndrome (MS)
Summary
It is established that patients with hyperlipidemia have a high risk of atherosclerosis and thrombotic complications, which are two important events responsible for the onset and progression of cardiovascular disease. Cardiovascular disease (CVD) is the main cause of increasing mortality worldwide. Dyslipidemia, the main risk factor for CVD, is a heterogeneous metabolic disorder involving multiple etiologies; it is commonly characterized by increased triglycerides, low-. In-vivo platelet activation has been reported in type-IIa hypercholesterolemic patients [11], suggesting that high levels of oxidized LDL, via changes in the composition of platelet membrane phospholipids and cholesterol, may increase the platelet reactivity associated with enhanced thromboxane A2 (TxA2) biosynthesis. The involvement of blood platelet activation in the onset of atherosclerosis is well established. The association of platelet activation with acute CVD justifies anti-platelet therapy as a standard treatment for those at high risk of atherothrombosis
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
